Anlotinib, a novel oral multitarget tyrosine kinase inhibitor, could inhibit VEGFR, PDGFR, FGFR, C-Kit, other kinases, and tumor angiogenesis- and proliferation-related signaling pathways (44). This evidence concerns the gene KIT and neoplasm.